

Literatur neuro aktuell Ausgabe 8-2019

Kopfschmerzen bei Kindern und Jugendlichen

F. Ebinger

Literatur:

1. Straube A, Heinen F, Ebinger F, von Kries R. Kopfschmerzen bei Schülern. *Dtsch Arztebl Int* 2013; 110: 811–818
2. Anttila P, Metsähonkala L, Sillanpää M. Long-term trends in the incidence of headache in Finnish schoolchildren. *Pediatrics* 2006; 117: 1197–1201
3. Bille B. Migraine in childhood and its prognosis. *Cephalalgia*. 1981; 1: 71–75
4. Bille B. A 40-year follow-up of school children with migraine. *Cephalalgia* 1997; 17: 488–491
5. Ebinger F. Der kindliche Kopfschmerz. Besserung in der Pubertät oder ein Erwachsenenschicksal? *Pädiatr Praxis* 2003; 64: 23–30
6. Headache Classification Committee of the International Headache Society. The international classification of headache disorders. 3rd ed. *Cephalalgia* 2018; 38: 1–211
7. Gaul C, Kraya T, Holle D, Benkel-Herrenbrück I, Schara U, Ebinger F. Migränevarianten und ungewöhnliche Manifestationen der Migräne im Kindesalter. *Der Schmerz* 2011; 25: 148–156
8. Lewis DW, Gozzo YF, Avner MT. The „other“ primary headaches in children and adolescents. *Pediatr Neurol* 2005; 33: 303–313.
9. Roser T, Bonfert M, Ebinger F, Blankenburg M, Ertl- Wagner B, Heinen F. Primary versus Secondary Headache in Children: A Frequent Diagnostic Challenge in Clinical Routine. *Neuropediatrics* 2013; 44: 34–39
10. Lewis DW, Ashwal S, Dahl G, Dorbad D, Hirtz D, Prensky A, Jarjour I: Practice parameter: evaluation of children and adolescents with recurrent headaches. *Neurology* 2003; 59: 490–498
11. Allmendinger A, Ebinger F. Diagnostik bei Kopfschmerzen im Kindesalter. *Kinder- und Jugendarzt* 2007; 38: 373–379
12. Bonfert M, Straube A, Schroeder AS, Reilich P, Ebinger F, Heinen F. Primary Headache in Children and Adolescents: Update on Pharmacotherapy of Migraine and Tension-Type Headache. *Neuropediatrics* 2013; 44: 3–19
13. Ebinger F: Kopfschmerzen. In: Korinthenberg R, Panteliadis CP, Hagel C (Hrsg.). *Neuropädiatrie. Evidenzbasierte Therapie*. München: Elsevier, Urban & Fischer, 3. Auflage, im Druck.
14. Richer L, Billingham L, Linsdell MA, Russell K, Vandermeer B, Crumley ET, Durec T, Klassen TP, Hartling L. Drugs for the acute treatment of migraine in children and adolescents. *Cochrane Database Syst Rev* 2016;4: CD005220. doi: 10.1002/14651858.CD005220.pub2
15. Fisher E, Law E, Dudeney J, Palermo TM, Stewart G, Eccleston C. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. *Cochrane Database Syst Rev*. 2018; 9: CD003968. doi:10.1002/14651858.CD003968.pub5
16. Kropp P, Meyer B, Landgraf M, Ruscheweyh R, Ebinger F, Straube A. Headache in Children: Update on Biobehavioral Treatments. *Neuropediatrics* 2013; 44: 20–24
17. Denecke H, Kröner-Herwig B: *Kopfschmerz-Therapie mit Kindern und Jugendlichen*. Göttingen, Bern, Toronto, Seattle: Hogrefe-Verlag 2000
18. Gerber WD, Gerber-von Müller G, Stephani U, Petermann F. *Kopfschmerzen bei Kindern und Jugendlichen. Das MIPASFamily- Programm*. Göttingen: Hogrefe Verlag; 2010
19. Richter M, Gruhl E, Lautenschläger E et al. DreKiP – ein ambulantes Therapieprogramm für Kinder und Jugendliche mit Kopfschmerzen. *Schmerz* 2018; 32: 17–29
20. Schlarb AA, Hautzinger M. Nichtmedikamentöse Therapie bei Kindern mit Migräne oder Spannungskopfschmerz. *Kinderund Jugendarzt* 2007; 38: 435–439
21. Seemann H: *Kopfschmerzkinder: Was Eltern, Lehrer und Therapeuten tun können*. Stuttgart: Klett-Cotta 2. Auflage, 2016
22. Shamlilian TA, Kane RL, Ramakrishnan R, Taylor FR. Migraine in Children: Preventive Pharmacologic Treatments. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Jun. Report No.: 13-EHC065-EF. AHRQ Comparative Effectiveness Reviews

23. Israel H, Neeb L, Reuter U. CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine. *Current Pain and Headache Reports* 2018; 22: 38
24. Evers S, Frese A, May A, Sixt G, Straube A: Therapie seltener idiopathischer Kopfschmerzkrankungen. *Nervenheilkunde* 2005; 24: 217–226
25. May A, Evers S, Straube A, Pfaffenrath V, Diener HC: Therapie und Prophylaxe von Clusterkopfschmerzen und anderen trigemino-autonomen Kopfschmerzen. *Nervenheilkunde* 2004; 23: 478–490

Interaktionen zwischen psychosozialen und neurologischen Einschränkungen in der Selbstbehandlung von chronischen Erkrankungen am Beispiel der Phenylketonurie (PKU)

S. Clever

Literatur:

1. Osterberg L, Blaschke T. Adherence to medication. *N Engl J Med* 2005; Aug4, 353(5): 487–497
2. Halm EA, Mora P, Leventhal H. No symptoms, no asthma: the acute episodic disease belief is associated with poor self-management among inner-city adults with persistent asthma. *Chest* 2006; 129(3): 573–80
3. Mohr DC, Goodkin DE, Likosky W et al. Therapeutic expectations of patients with MS upon initiating interferon beta-1b: relationship to adherence to treatment. *Mult Scler* 1996; 2(5): 222–226
4. Brown TM, Siu K, Walker D et al. Development of a conceptual model of adherence to oral anticoagulants to reduce the risk of stroke in patients with atrial fibrillation. *J Manag Care Pharm* 2012; 18(5): 351–62
5. van Rijn MacDonald M, Feillet FL und AM et al. Adherence issues in inherited metabolic disorders treated by low natural protein diets. *Ann Nutr Metab* 2012; 61: 289–295
6. Jurecki ER, Cederbaum S, Kopesky J et al. Adherence to clinic recommendations among patients with phenylketonuria in the United States. *Mol Genet Metab* 2017; 120: 190–197
7. Walter JH, White FJ, Hall SK et al. How practical are recommendations for dietary control in phenylketonuria? *Lancet* 2002; 360(9326): 55–57
8. van Spronsen FJ, van Wegberg AM, Ahring K et al. Key European guidelines for the diagnosis and management of patients with phenylketonuria. *Lancet Diabetes Endocrinol* 2017; 5(9):743–756
9. Conner M und Norman P. *Predicting health behavior*. Open University Press 2005
10. Waisbren S, Noel K, Fahrback K et al. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. *Mol Genet Metab* 2007; 92(1–2): 63–70
11. Blau N, Belanger-Quintana A, Demirkol M et al. Management of phenylketonuria in Europe: survey results from 19 countries. *Mol Genet Metab* 2010; 99(2): 109–15
12. Zulman DM, Rosland AM, Choi H et al. The influence of diabetes psychosocial attributes and self-management practices on change in diabetes status. *Patient Educ Couns* 2012; 87(1): 74–80
13. Cazzorla C, Bensi G, Biasucci G et al. Living with PKU in adulthood: The PKU ATTITUDE study. *Mol Gen and Met Rep* 2018; 16: 39–45
14. Diesen PS, Wiig I, Grut L, Kase BF. Betwixt and between being healthy and ill: the stigma experienced by young adults with phenylketonuria. *Scandinavian Journal of Disability Research* 2015; 17(4): 321–334

15. Bilder DA, Noel JK, Baker ER et al. Systematic Review and Meta-Analysis of Neuropsychiatric Symptoms and Executive Functioning in Adults With Phenylketonuria. *Dev Neuropsychol* 2016; 18, 41(4): 245–260
16. Ford S, O'Driscoll M, MacDonald A. Living with Phenylketonuria: Lessons from the PKU community. *Mol Gen and Metab Rep* 2018; 17: 57–63
17. Burlina AP, Lachmann RH, Manara R et al. The neurological and psychological phenotype of adult patients with early treated phenylketonuria: A systematic review. *J Inher Metab Dis*. 2019; 42(2): 209–219
18. Woods S. Psychologische Standards in der Diabetesschulung: die Patienten verstehen in Psychodiabetologie, Herausg. Lange K. und Hirsch A. 2002; Kirchheim-Verlag
19. Cox DJ, Kovatchev BP, Gonder-Frederick LA et al. Relationships between hyperglycemia and cognitive performance among adults with type 1 and type 2 diabetes. *Diabetes Care* 2005; 28(1): 71–77
20. Sommerfield AJ, Deary IJ, Frier BM. Acute Hyperglycemia alters mood state and impairs cognitive performance in people with type 2 diabetes. *Diabetes Care* 2004; 27(10): 2335–2340
21. Brundisini F, Vanstone M, Hulan D et al. Type 2 diabetes patients „and providers“ differings persepectives on medication non-adherence: a qualitative meta-synthesis. *BMC Health Serv Res* 2015; 23(15): 516

Glycyrrhizinsäure aus der Süßholzwurzel – ein selektiver Hemmstoff der Kynureninaminotransferase
2

J. Bielenberg

Literatur

1. Yoshida Y, Fujigaki H, Kato K, et al. Selective and competitive inhibition of kynurenine aminotransferase 2 by glycyrrhizic acid and its analogues. *Sci Rep* 2019, 9: 10243
2. Linderholm KR et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. *Schizophrenia bulletin*. 2012; 38: 426–432. doi: 10.1093/schbul/sbq086
3. Schwarcz R et al. Increased cortical kynurenate content in schizophrenia. *Biological psychiatry*. 2001; 50: 521–530. doi: 10.1016/S0006-3223(01)01078-2
4. Erhardt S et al. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. *Neuroscience letters*. 2001; 313: 96–98. doi: 10.1016/S0304-3940(01)02242-X
5. Leonard B & Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. *Neurosci Biobehav Rev* 2012; 36: 764–85. doi:10.1016/j.neubiorev.2011.12.005
6. Tabuchi M, Imamura S, Kawakami Z et al. The blood-brain barrier permeability of 18beta-glycyrrhetic acid, a major metabolite of glycyrrhizin in *Glycyrrhiza* root, a constituent of the traditional Japanese medicine yokukansan. *Cellular and molecular neurobiology*. 2012; 32: 1139–1146. doi: 10.1007/s10571-012-9839-x

7. Miyaoka T et al. Yokukansan (TJ-54) for treatment of very-late-onset schizophrenia-like psychosis: an open-label study. *Phytomedicine: international journal of phytotherapy and phytopharmacology*. 2013; 20: 654–658. doi: 10.1016/j.phymed.2013.01.007
8. Miyaoka T et al. Yi-gan san as adjunctive therapy for treatment-resistant schizophrenia: an open-label study. *Clinical neuropharmacology* 2009; 32: 6–9. doi: 10.1097/WNF.0b013e31817e08c3
9. Monji A et al. Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer's disease. *Progress in neuro-psychopharmacology & biological psychiatry* 2009; 33: 308–311. doi: 10.1016/j.pnpbp.2008.12.008
10. Mizukami K et al. A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia. *The international journal of neuropsychopharmacology*. 2009; 12: 191–199. doi: 10.1017/S146114570800970X
11. Iwasaki K et al. A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. *The Journal of clinical psychiatry* 2005; 66: 248–252. doi: 10.4088/JCP.v66n0214
12. Sandeep T, Yau JLW, Maclulich AMJ et al. β -Hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. *PNAS* 101(17), 27.04.2004
13. Takeuchi H et al. Blockade of Gap junction hemichannel suppresses disease progression in Mouse models of amyotrophic lateral sclerosis and Alzheimer disease. *PloS One* 2011; 21, 6(6) Epub 2011
14. Bortz DM, Wu HQ, Schwarcz R, Bruno JP. Oral administration of a specific kynurenic acid synthesis (KAT II) inhibitor attenuates evoked glutamate release in rat prefrontal cortex. *Neuropharmacology* 2017; 15(121): 69–78